ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå, ±Ô¸ð, Á¡À¯À², µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : Á¦Ç° À¯Çüº°, °Ë»ç À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° - ½ÃÀå ¿¹Ãø(2025-2034³â)
Autoimmune Disease Diagnostics Market Size, Share, Trends, Industry Analysis Report: By Product, Type, Test Type, End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034
»óǰÄÚµå : 1625479
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 6,149,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,596,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 9,043,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, ¼¼°è ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 71¾ï 4,632¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Á¶»ç º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÅëÂû·Â°ú ¹Ì·¡ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀåÀº ÇコÄÉ¾î ¹× Áø´Ü »ê¾÷ÀÇ ÇÑ ºÐ¾ßÀÔ´Ï´Ù. ÀÌ ½ÃÀåÀº ÷´Ü Áø´Ü µµ±¸¿Í ±â¼úÀ» ÅëÇØ ÀÚ°¡¸é¿ªÁúȯÀ» ½Äº°ÇÏ°í °ü¸®ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ÀÚ°¡¸é¿ªÁúȯÀº ¸é¿ªÃ¼°è°¡ ½Åü Á¶Á÷À» °ø°ÝÇÏ¿© ¸¸¼ºÀûÀ̰í ÀáÀçÀûÀ¸·Î ´Ù¾çÇÑ Áõ»óÀ» À¯¹ßÇÏ´Â ÁúȯÀÔ´Ï´Ù. ÀÌ ½ÃÀåÀº Ç÷¾× °Ë»ç, ¿µ»ó Áø´Ü ±â¼ú, ºÐÀÚ ºÐ¼® µî ÀÌ·¯ÇÑ »óŸ¦ °¨ÁöÇÏ´Â µ¥ »ç¿ëµÇ´Â Áø´Ü °Ë»ç ¹× ±â¼úÀ» Æ÷°ýÇÕ´Ï´Ù.

Àü ¼¼°èÀûÀ¸·Î ÀÚ°¡¸é¿ªÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¶±â¿¡ Á¤È®ÇÑ Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ȯÀÚ¿Í ÀÇ·áÁøÀº º¸´Ù Á¤È®Çϰí È¿À²ÀûÀÎ Áø´Ü ¼Ö·ç¼ÇÀ» ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °³ÀÎ ¸ÂÃãÇü ÀÇ·á ¹× Ã·´Ü Ä¡·á Á¢±Ù¹ýÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¤È®ÇÑ Áø´ÜÀÌ ÇÊ¿äÇØÁö¸é¼­ ½ÃÀå ¼ºÀå¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ÀÚ°¡¸é¿ª Áúȯ ¹× Áø´Ü ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê¿Í ÀÚ±Ý Áö¿øÀº »õ·Î¿î Áø´Ü ¹æ¹ýÀÇ °³¹ß¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ÀÌ·Î ÀÎÇØ ½ÃÀå ±âȸ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

2021³â AMP(Accelerating Medicines Partnership) ÇÁ·Î±×·¥Àº AMP AIM(Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases) ÇÁ·Î±×·¥À» µµÀÔÇß½À´Ï´Ù. AMP AIM(AMP Autoimmune and Immune-Mediated Diseases) ÀÌ´Ï¼ÅÆ¼ºê´Â ÀÚ°¡¸é¿ªÁúȯ¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̰í Á¶±â °ËÁøÀ» ÃËÁøÇÔÀ¸·Î½á ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀåÀº ´õ ³ôÀº Á¤È®µµ¿Í ºü¸¥ °á°ú¸¦ Á¦°øÇÏ´Â °íµµÀÇ ÀÚµ¿È­µÈ Áø´Ü ¼Ö·ç¼ÇÀ¸·Î ºü¸£°Ô ÀüȯÇϰí ÀÖ½À´Ï´Ù. ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×(ML)À» Áø´Ü Ç÷§Æû¿¡ ÅëÇÕÇÔÀ¸·Î½á ÀÚ°¡¸é¿ªÁúȯÀ» °¨ÁöÇÏ°í ¸ð´ÏÅ͸µÇÏ´Â ¹æ¹ýÀ» º¯È­½ÃÄÑ È¿À²¼º°ú Á¤È®¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±âÁ¸ ¹æ¹ýº¸´Ù ȯÀÚ Ä£È­ÀûÀÎ ºñħ½ÀÀû Áø´Ü ±â¼ú °³¹ß¿¡ Á¡Á¡ ´õ ¸¹Àº °ü½ÉÀÌ ÁýÁߵǰí ÀÖ½À´Ï´Ù.

Áö³­ 7¿ù, KSL Beutner Laboratories(Beutner)´Â ¹Ì±¹¿¡¼­ °£Á¢ ¸é¿ª Çü±¤(IIF) Ç÷û Ç÷¾× °Ë»ç¸¦ ½ÃÀÛÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ °Ë»ç´Â Áö¼Ó¼º ÀÚ°¡¸é¿ªÁúȯÀÎ Á¡¸· õÆ÷â(MMP)°ú °ü·ÃµÈ Ç׿øÀÎ ¶ó¹Ì´Ñ332¸¦ È¿°úÀûÀ¸·Î °ËÃâÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áø´Ü¹ýÀÇ ¹ßÀüÀº ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

À¯Çüº°·Î´Â Àü½Å¼º ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ºÎ¹®ÀÌ ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀåÀÇ ¸ÅÃâ Á¡À¯À²À» ÁÖµµÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ÁÖ·Î ÀÇ·áÁø°ú ȯÀÚµéÀÇ ÀÎ½Ä °³¼±¿¡ ±âÀÎÇÕ´Ï´Ù.

°Ë»ç À¯Çüº°·Î´Â ÀÚ°¡¸é¿ªÁúȯÀÇ À¯º´·ü Áõ°¡¿Í Áø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î Ç×ÇÙÇ×ü(ANA) °Ë»ç ºÐ¾ß°¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì´Â ÷´Ü ÀÇ·á ÀÎÇÁ¶ó¿Í ÀÇ·á ¿¬±¸°³¹ßÀ» À§ÇÑ ¸·´ëÇÑ ÀÚ±ÝÀ¸·Î ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº Áß±¹, Àεµ µî ±¹°¡ÀÇ ÀÇ·á ºÎ¹® ¼ºÀå°ú ÀÚ°¡¸é¿ªÁúȯ À¯º´·ü Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷À¸·Î´Â Abbott, AESKU.DIAGNOSTICS, Beckman Coulter, BIOMERIEUX, Bio-Rad Laboratories, EUROIMMUN, F. Hoffmann-La Roche Ltd, Inova Diagnostics(Werfen Group), Myriad Genetics, Quest Diagnostics, Scipher Medicine, Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc. µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå ÀλçÀÌÆ®

  • PESTEL ºÐ¼®
  • ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå À¯Çü µ¿Çâ
  • ¹ë·ùüÀÎ ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®

    Á¦5Àå ¼¼°èÀÇ ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå : Á¦Ç°º°

    • ÁÖ¿ä Á¶»ç °á°ú
    • ¼­·Ð
    • ¼Ò¸ðǰ ¹× ¾î¼¼ÀÌ Å°Æ®
    • ±â±â

    Á¦6Àå ¼¼°èÀÇ ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå : À¯Çüº°

    • ÁÖ¿ä Á¶»ç °á°ú
    • ¼­·Ð
    • Àü½Å¼º ÀÚ°¡¸é¿ªÁúȯ Áø´Ü
    • ±¹¼ÒÀû ÀÚ°¡¸é¿ªÁúȯ Áø´Ü

    Á¦7Àå ¼¼°èÀÇ ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå : °Ë»ç À¯Çüº°

    • ÁÖ¿ä Á¶»ç °á°ú
    • ¼­·Ð
    • Ç×ÇÙ Ç×ü(ANA) °Ë»ç
    • ÀÚ°¡ Ç×ü °Ë»ç
    • ÀüÇ÷±¸¼ö(CBC)
    • Á¾ÇÕÀû ´ë»ç ÆÐ³Î
    • C¹ÝÀÀ¼º ´Ü¹éÁú(CRP)
    • ±âŸ

    Á¦8Àå ¼¼°èÀÇ ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

    • ÁÖ¿ä Á¶»ç °á°ú
    • ¼­·Ð
    • º´¿ø
    • Áø´Ü¼¾ÅÍ
    • ¿¬±¸½Ç

    Á¦9Àå ¼¼°èÀÇ ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå : Áö¿ªº°

    • ÁÖ¿ä Á¶»ç °á°ú
    • ¼­·Ð
      • ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå Æò°¡ : Áö¿ªº°, 2020³â-2034³â
    • ºÏ¹Ì
      • ºÏ¹Ì : Á¦Ç°º°, 2020³â-2034³â
      • ºÏ¹Ì : À¯Çüº°, 2020³â-2034³â
      • ºÏ¹Ì : °Ë»ç À¯Çüº°, 2020³â-2034³â
      • ºÏ¹Ì : ÃÖÁ¾»ç¿ëÀÚº°, 2020-2034³â
      • ¹Ì±¹
      • ij³ª´Ù
    • À¯·´
      • À¯·´ : Á¦Ç°º°, 2020³â-2034³â
      • À¯·´ : À¯Çüº°, 2020³â-2034³â
      • À¯·´ : °Ë»ç À¯Çüº°, 2020³â-2034³â
      • À¯·´ : ÃÖÁ¾»ç¿ëÀÚº°, 2020-2034³â
      • ¿µ±¹
      • ÇÁ¶û½º
      • µ¶ÀÏ
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ³×´ú¶õµå
      • ·¯½Ã¾Æ
      • ±âŸ À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • ¾Æ½Ã¾ÆÅÂÆò¾ç : Á¦Ç°º°, 2020-2034³â
      • ¾Æ½Ã¾ÆÅÂÆò¾ç : À¯Çüº°, 2020³â-2034³â
      • ¾Æ½Ã¾ÆÅÂÆò¾ç : °Ë»ç À¯Çüº°, 2020³â-2034³â
      • ¾Æ½Ã¾ÆÅÂÆò¾ç : ÃÖÁ¾»ç¿ëÀÚº°, 2020-2034³â
      • Áß±¹
      • Àεµ
      • ¸»·¹À̽þÆ
      • ÀϺ»
      • Àεµ³×½Ã¾Æ
      • Çѱ¹
      • È£ÁÖ
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Á¦Ç°º°, 2020-2034³â
      • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : À¯Çüº°, 2020-2034³â
      • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : °Ë»ç À¯Çüº°, 2020³â-2034³â
      • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ÃÖÁ¾»ç¿ëÀÚº°, 2020³â-2034³â
      • »ç¿ìµð¾Æ¶óºñ¾Æ
      • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
      • À̽º¶ó¿¤
      • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä«
      • ¶óƾ¾Æ¸Þ¸®Ä« : Á¦Ç°º°, 2020³â-2034³â
      • ¶óƾ¾Æ¸Þ¸®Ä« : À¯Çüº°, 2020³â-2034³â
      • ¶óƾ¾Æ¸Þ¸®Ä« : °Ë»ç À¯Çüº°, 2020³â-2034³â
      • ¶óƾ¾Æ¸Þ¸®Ä« : ÃÖÁ¾»ç¿ëÀÚº°, 2020-2034³â
      • ¸ß½ÃÄÚ
      • ºê¶óÁú
      • ¾Æ¸£ÇîÆ¼³ª
      • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«

    Á¦10Àå °æÀï ±¸µµ

    • È®´ë¿Í Àμö ºÐ¼®
      • È®´ë
      • Àμö
    • Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³

    Á¦11Àå ±â¾÷ °³¿ä

    • Abbott
    • AESKU.DIAGNOSTICS
    • Beckman Coulter, Inc.
    • BIOMERIEUX
    • Bio-Rad Laboratories, Inc.
    • EUROIMMUN
    • F. Hoffmann-La Roche Ltd
    • Inova Diagnostics(Werfen Group)
    • Myriad Genetics, Inc.
    • Quest Diagnostics
    • Scipher Medicine
    • Siemens Healthcare Private Limited
    • Thermo Fisher Scientific Inc.
    LSH
  • ¿µ¹® ¸ñÂ÷

    ¿µ¹®¸ñÂ÷

    The global autoimmune disease diagnostics market size is expected to reach USD 7,146.32 million by 2034, according to a new study by Polaris Market Research. The report "Autoimmune Disease Diagnostics Market Size, Share, Trends, Industry Analysis Report: By Product, Type, Test Type, End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034." gives a detailed insight into current market dynamics and provides analysis on future market growth.

    The autoimmune disease diagnostics market is a sector within the healthcare and diagnostic industry. The market focuses on the identification and management of autoimmune diseases through advanced diagnostic tools and techniques. Autoimmune diseases occur when the immune system attacks the body's tissues, leading to a range of chronic and potential conditions. The market encompasses diagnostic tests and technologies used to detect these conditions, including blood tests, imaging techniques, and molecular assays.

    The increasing prevalence of autoimmune diseases globally drives demand for early and accurate diagnostic tools. As awareness of these conditions grows, patients and healthcare providers seek more precise and efficient diagnostic solutions. Additionally, the rising adoption of personalized medicine and advanced treatment approaches necessitates accurate diagnostics, further boosting market growth. Government initiatives and funding for research into autoimmune diseases and diagnostics are contributing to the development of new diagnostic methods, thereby enhancing market opportunities.

    In 2021, the Accelerating Medicines Partnership (AMP) program introduced the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) program. The AMP Autoimmune and Immune-Mediated Diseases (AMP AIM) initiative is driving the market by increasing awareness and promoting early screening for autoimmune diseases.

    The autoimmune disease diagnostics market is experiencing swift to advanced and automated diagnostic solutions that provide higher accuracy and faster results. Integration of artificial intelligence (AI) and machine learning (ML) into diagnostic platforms is transforming how autoimmune diseases are detected and monitored, improving efficiency and precision. Furthermore, there is an increasing focus on developing noninvasive diagnostic techniques, which provide a more patient-friendly alternative to traditional methods.

    In July 2022, KSL Beutner Laboratories (Beutner) announced the launch of an indirect immunofluorescence (IIF) serum blood test in the US. The test effectively detects laminin 332, an antigen linked to the persistent autoimmune condition mucous membrane pemphigoid (MMP). These increasing developments in diagnostic methods drive the autoimmune disease diagnostics market growth.

    Autoimmune Disease Diagnostics Market Report Highlights

    Based on type, the systemic autoimmune disease diagnostics segment dominated the autoimmune disease diagnostics market revenue share, mainly attributed to increased awareness among healthcare providers and patients.

    The antinuclear antibody (ANA) tests segment, by test type, is expected to register the highest CAGR during the forecast period, owing to the increasing prevalence of autoimmune diseases and advancements in diagnostic technologies.

    North America dominated the market due to advanced healthcare infrastructure and substantial funding for medical research and development.

    Asia Pacific is expected to register the highest CAGR during the forecast period, owing to growing healthcare sectors in countries such as China and India and the increasing prevalence of autoimmune diseases.

    A few global key market players are Abbott; AESKU.DIAGNOSTICS; Beckman Coulter, Inc.; BIOMERIEUX; Bio-Rad Laboratories, Inc.; EUROIMMUN; F. Hoffmann-La Roche Ltd; Inova Diagnostics (Werfen Group); Myriad Genetics, Inc.; Quest Diagnostics; Scipher Medicine; Siemens Healthcare Private Limited; and Thermo Fisher Scientific Inc.

    Polaris Market Research has segmented the autoimmune disease diagnostics market report on the basis of product, type, test type, end user, and region:

    By Product Outlook (Revenue - USD Million, 2020-2034)

    By Type Outlook (Revenue - USD Million, 2020-2034)

    By Test Type Outlook (Revenue - USD Million, 2020-2034)

    By End User Outlook (Revenue - USD Million, 2020-2034)

    By Regional Outlook (Revenue - USD Million, 2020-2034)

    Table of Contents

    1. Introduction

    2. Executive Summary

    3. Research Methodology

    4. Global Autoimmune Disease Diagnostics Market Insights

    5. Global Autoimmune Disease Diagnostics Market, by Product

    6. Global Autoimmune Disease Diagnostics Market, by Type

    7. Global Autoimmune Disease Diagnostics Market, by Test Type

    8. Global Autoimmune Disease Diagnostics Market, by End User

    9. Global Autoimmune Disease Diagnostics Market, by Geography

    10. Competitive Landscape

    11. Company Profiles

    (ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
    ¨Ï Copyright Global Information, Inc. All rights reserved.
    PC¹öÀü º¸±â